Results 171 to 180 of about 4,898 (191)

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015

International Journal of Antimicrobial Agents, 2019
James Karlowsky, Yoshinori Yamano, Meredith A Hackel   +2 more
exaly  

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

International Journal of Antimicrobial Agents, 2019
Mark Wise, Krystyna Kaźmierczak, Yoshinori Yamano   +2 more
exaly  

Synthesis of Cefiderocol

Synfacts, 2018
openaire   +1 more source

Cefiderocol/colistin/tigecycline

Reactions Weekly, 2021
openaire   +1 more source

Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function

Antimicrobial Agents and Chemotherapy, 2017
Takayuki Katsube, Toru Ishibashi, Juan Camilo Arjona Ferreira   +2 more
exaly  

ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases

Antimicrobial Agents and Chemotherapy, 2019
Robert Bonomo, Michael Jacobs, Daniel D Rhoads   +2 more
exaly  

Cefiderocol (S-649266)

2017
Cefiderocol (S-649266) is a novel siderophore cephalosporin, initially developed jointly by Shionogi Inc. and Glaxo Smith Kline. From November 9, 2015, further development was by Shio nogi alone. By virtue of in vitro activity against carbapenem- resistant Enterobacteriaceae (CRE), including those producing Klebsiella pneumoniae carbapenemase (KPC ...
openaire   +2 more sources

Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin

Clinical Infectious Diseases, 2019
Takayuki Katsube, Roger Echols, Echols Roger   +2 more
exaly  

Cefiderocol/colistin

Reactions Weekly
openaire   +2 more sources

Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis

International Journal of Antimicrobial Agents
Maddalena Giannella, Federico Pèa, Pierluigi Viale   +2 more
exaly